211 related articles for article (PubMed ID: 27151345)
1. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.
Vranckx P; White HD; Huang Z; Mahaffey KW; Armstrong PW; Van de Werf F; Moliterno DJ; Wallentin L; Held C; Aylward PE; Cornel JH; Bode C; Huber K; Nicolau JC; Ruzyllo W; Harrington RA; Tricoci P
J Am Coll Cardiol; 2016 May; 67(18):2135-2144. PubMed ID: 27151345
[TBL] [Abstract][Full Text] [Related]
2. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Vranckx P; Leonardi S; Tebaldi M; Biscaglia S; Parrinello G; Rao SV; Mehran R; Valgimigli M
Eur Heart J; 2014 Oct; 35(37):2524-9. PubMed ID: 24755007
[TBL] [Abstract][Full Text] [Related]
4. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Valgimigli M; Costa F; Lokhnygina Y; Clare RM; Wallentin L; Moliterno DJ; Armstrong PW; White HD; Held C; Aylward PE; Van de Werf F; Harrington RA; Mahaffey KW; Tricoci P
Eur Heart J; 2017 Mar; 38(11):804-810. PubMed ID: 28363222
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications.
Kikkert WJ; van Geloven N; van der Laan MH; Vis MM; Baan J; Koch KT; Peters RJ; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
J Am Coll Cardiol; 2014 May; 63(18):1866-75. PubMed ID: 24657697
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
8. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
[TBL] [Abstract][Full Text] [Related]
9. A risk score to predict bleeding in patients with acute coronary syndromes.
Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
[TBL] [Abstract][Full Text] [Related]
10. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Alfredsson J; Neely B; Neely ML; Bhatt DL; Goodman SG; Tricoci P; Mahaffey KW; Cornel JH; White HD; Fox KA; Prabhakaran D; Winters KJ; Armstrong PW; Ohman EM; Roe MT;
Heart; 2017 Aug; 103(15):1168-1176. PubMed ID: 28381584
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
Vavalle JP; Clare R; Chiswell K; Rao SV; Petersen JL; Kleiman NS; Mahaffey KW; Wang TY
JACC Cardiovasc Interv; 2013 Jul; 6(7):709-17. PubMed ID: 23866183
[TBL] [Abstract][Full Text] [Related]
13. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of new bleeding criteria: a prospective study of evaluation for the Bleeding Academic Research Consortium definition of bleeding in patients undergoing percutaneous coronary intervention.
Choi JH; Seo JM; Lee DH; Park K; Kim YD
J Cardiol; 2015 Apr; 65(4):324-9. PubMed ID: 25066338
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
[TBL] [Abstract][Full Text] [Related]
16. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
17. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Ducrocq G; Schulte PJ; Becker RC; Cannon CP; Harrington RA; Held C; Himmelmann A; Lassila R; Storey RF; Sorbets E; Wallentin L; Steg PG
EuroIntervention; 2015 Nov; 11(7):737-45. PubMed ID: 25254357
[TBL] [Abstract][Full Text] [Related]
18. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
20. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
